Last reviewed · How we verify
TPN171H single dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TPN171H single dose (TPN171H single dose) — Vigonvita Life Sciences.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TPN171H single dose TARGET | TPN171H single dose | Vigonvita Life Sciences | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TPN171H single dose CI watch — RSS
- TPN171H single dose CI watch — Atom
- TPN171H single dose CI watch — JSON
- TPN171H single dose alone — RSS
Cite this brief
Drug Landscape (2026). TPN171H single dose — Competitive Intelligence Brief. https://druglandscape.com/ci/tpn171h-single-dose. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing